Regeneron Pharmaceuticals, Inc.REGNNASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, below historical average, slight contraction.
Left:
||||
Year-over-year operating income growth rate
Latest
-4.88%
↓ 150% below average
Average (39q)
9.79%
Historical baseline
Range
High:200.82%
Low:-51.26%
CAGR
-5.3%
Structural decline
| Period | Value |
|---|---|
| Q3 2025 | -4.88% |
| Q2 2025 | 82.44% |
| Q1 2025 | -40.24% |
| Q4 2024 | -16.05% |
| Q3 2024 | 10.27% |
| Q2 2024 | 42.35% |
| Q1 2024 | -28.49% |
| Q4 2023 | -13.24% |
| Q3 2023 | 19.13% |
| Q2 2023 | 1.37% |
| Q1 2023 | -23.76% |
| Q4 2022 | 7.49% |
| Q3 2022 | -6.37% |
| Q2 2022 | 1.58% |
| Q1 2022 | -51.26% |
| Q4 2021 | 42.90% |
| Q3 2021 | -44.81% |
| Q2 2021 | 200.82% |
| Q1 2021 | -4.65% |
| Q4 2020 | 10.82% |
| Q3 2020 | 60.44% |
| Q2 2020 | -6.24% |
| Q1 2020 | 3.61% |
| Q4 2019 | -8.50% |
| Q3 2019 | 134.00% |
| Q2 2019 | -34.25% |
| Q1 2019 | -33.16% |
| Q4 2018 | 14.54% |
| Q3 2018 | 0.76% |
| Q2 2018 | 9.69% |
| Q1 2018 | 5.27% |
| Q4 2017 | -3.77% |
| Q3 2017 | 1.75% |
| Q2 2017 | 27.82% |
| Q1 2017 | 24.07% |
| Q4 2016 | -4.35% |
| Q3 2016 | 24.41% |
| Q2 2016 | -11.44% |
| Q1 2016 | 42.51% |
| Q4 2015 | -41.11% |